An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Rapid Micro Biosystems, Inc. (RPID) will announce its first quarter 2024 financial results on May 3, 2024. The company specializes in life sciences technology, providing automation solutions for healthcare product manufacturing. The management team will host a webcast conference call at 8:30 a.m. ET on the same day.
Rapid Micro Biosystems, Inc. (RPID) annuncerà i suoi risultati finanziari del primo trimestre 2024 il 3 maggio 2024. L'azienda è specializzata in tecnologie per le scienze della vita, fornendo soluzioni di automazione per la produzione di prodotti sanitari. Il team di gestione ospiterà una conferenza webcast alle 8:30 a.m. ET dello stesso giorno.
Rapid Micro Biosystems, Inc. (RPID) anunciará sus resultados financieros del primer trimestre de 2024 el 3 de mayo de 2024. La empresa se especializa en tecnología de ciencias de la vida, proporcionando soluciones de automatización para la fabricación de productos sanitarios. El equipo de gestión organizará una llamada de conferencia por webcast a las 8:30 a.m. ET ese mismo día.
Rapid Micro Biosystems, Inc. (RPID)는 2024년 5월 3일에 2024년 1분기 재무 결과를 발표할 예정입니다. 이 회사는 생명 과학 기술을 전문으로 하며, 의료제품 제조를 위한 자동화 솔루션을 제공합니다. 경영진은 같은 날 동부 표준시 오전 8시 30분에 웹캐스트 콘퍼런스 콜을 주관할 것입니다.
Rapid Micro Biosystems, Inc. (RPID) annoncera ses résultats financiers pour le premier trimestre 2024 le 3 mai 2024. L'entreprise est spécialisée dans la technologie des sciences de la vie, fournissant des solutions d'automatisation pour la fabrication de produits de santé. L'équipe de direction organisera une conférence téléphonique via webcast à 8h30 ET le même jour.
Rapid Micro Biosystems, Inc. (RPID) wird seine Finanzergebnisse für das erste Quartal 2024 am 3. Mai 2024 bekannt geben. Das Unternehmen ist auf Technologien für die Lebenswissenschaften spezialisiert und bietet Automatisierungslösungen für die Herstellung von Gesundheitsprodukten an. Das Managementteam wird am selben Tag um 8:30 Uhr ET einen Webcast-Konferenzanruf veranstalten.
Positive
None.
Negative
None.
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 3, 2024. The live webcast will be accessible on the Company’s website here and will be available for replay for one year from the webcast date.
About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.
